Cargando…

Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy

Puberty in children with Prader-Willi syndrome (PWS) is usually delayed and/or incomplete but in some patients premature/early adrenarche is observed. We assessed the premature adrenarche (PA) in PWS patients during the recombinant human growth hormone (rhGH) therapy and influence of PA on the cours...

Descripción completa

Detalles Bibliográficos
Autores principales: Lecka-Ambroziak, Agnieszka, Wysocka-Mincewicz, Marta, Marszałek-Dziuba, Kamila, Rudzka-Kocjan, Agnieszka, Szalecki, Mieczysław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600779/
https://www.ncbi.nlm.nih.gov/pubmed/33050529
http://dx.doi.org/10.3390/life10100237
_version_ 1783603234504441856
author Lecka-Ambroziak, Agnieszka
Wysocka-Mincewicz, Marta
Marszałek-Dziuba, Kamila
Rudzka-Kocjan, Agnieszka
Szalecki, Mieczysław
author_facet Lecka-Ambroziak, Agnieszka
Wysocka-Mincewicz, Marta
Marszałek-Dziuba, Kamila
Rudzka-Kocjan, Agnieszka
Szalecki, Mieczysław
author_sort Lecka-Ambroziak, Agnieszka
collection PubMed
description Puberty in children with Prader-Willi syndrome (PWS) is usually delayed and/or incomplete but in some patients premature/early adrenarche is observed. We assessed the premature adrenarche (PA) in PWS patients during the recombinant human growth hormone (rhGH) therapy and influence of PA on the course of central puberty (CP), rhGH efficacy and safety, and patients’ metabolic state. Forty-nine PWS patients were treated with rhGH, 11 presented with PA (group 1) and 14 had normal course of adrenarche (group 2). PA was observed in 22.5% of the PWS children treated with rhGH. The mean time between the rhGH start and the adrenarche, the rhGH dose, the growth velocity and the insulin-like growth factor 1 SD (IGF1 SD) during the treatment, as well as the time of CP, final height SD and BMI SD were similar in both groups. There were also no significant differences in the metabolic assessment—the oral glucose tolerance test (OGTT) and lipid profile results. PA may be a part of the clinical picture of PWS, apart from hypogonadotrophic hypogonadism and it seems to have no influence on CP in PWS patients. The rhGH efficacy and safety were comparable in the patients with PA and the normal course of adrenarche.
format Online
Article
Text
id pubmed-7600779
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76007792020-11-01 Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy Lecka-Ambroziak, Agnieszka Wysocka-Mincewicz, Marta Marszałek-Dziuba, Kamila Rudzka-Kocjan, Agnieszka Szalecki, Mieczysław Life (Basel) Article Puberty in children with Prader-Willi syndrome (PWS) is usually delayed and/or incomplete but in some patients premature/early adrenarche is observed. We assessed the premature adrenarche (PA) in PWS patients during the recombinant human growth hormone (rhGH) therapy and influence of PA on the course of central puberty (CP), rhGH efficacy and safety, and patients’ metabolic state. Forty-nine PWS patients were treated with rhGH, 11 presented with PA (group 1) and 14 had normal course of adrenarche (group 2). PA was observed in 22.5% of the PWS children treated with rhGH. The mean time between the rhGH start and the adrenarche, the rhGH dose, the growth velocity and the insulin-like growth factor 1 SD (IGF1 SD) during the treatment, as well as the time of CP, final height SD and BMI SD were similar in both groups. There were also no significant differences in the metabolic assessment—the oral glucose tolerance test (OGTT) and lipid profile results. PA may be a part of the clinical picture of PWS, apart from hypogonadotrophic hypogonadism and it seems to have no influence on CP in PWS patients. The rhGH efficacy and safety were comparable in the patients with PA and the normal course of adrenarche. MDPI 2020-10-10 /pmc/articles/PMC7600779/ /pubmed/33050529 http://dx.doi.org/10.3390/life10100237 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lecka-Ambroziak, Agnieszka
Wysocka-Mincewicz, Marta
Marszałek-Dziuba, Kamila
Rudzka-Kocjan, Agnieszka
Szalecki, Mieczysław
Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy
title Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy
title_full Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy
title_fullStr Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy
title_full_unstemmed Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy
title_short Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy
title_sort premature adrenarche in children with prader-willi syndrome treated with recombinant human growth hormone seems to not influence the course of central puberty and the efficacy and safety of the therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600779/
https://www.ncbi.nlm.nih.gov/pubmed/33050529
http://dx.doi.org/10.3390/life10100237
work_keys_str_mv AT leckaambroziakagnieszka prematureadrenarcheinchildrenwithpraderwillisyndrometreatedwithrecombinanthumangrowthhormoneseemstonotinfluencethecourseofcentralpubertyandtheefficacyandsafetyofthetherapy
AT wysockamincewiczmarta prematureadrenarcheinchildrenwithpraderwillisyndrometreatedwithrecombinanthumangrowthhormoneseemstonotinfluencethecourseofcentralpubertyandtheefficacyandsafetyofthetherapy
AT marszałekdziubakamila prematureadrenarcheinchildrenwithpraderwillisyndrometreatedwithrecombinanthumangrowthhormoneseemstonotinfluencethecourseofcentralpubertyandtheefficacyandsafetyofthetherapy
AT rudzkakocjanagnieszka prematureadrenarcheinchildrenwithpraderwillisyndrometreatedwithrecombinanthumangrowthhormoneseemstonotinfluencethecourseofcentralpubertyandtheefficacyandsafetyofthetherapy
AT szaleckimieczysław prematureadrenarcheinchildrenwithpraderwillisyndrometreatedwithrecombinanthumangrowthhormoneseemstonotinfluencethecourseofcentralpubertyandtheefficacyandsafetyofthetherapy